Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality and comprises molecular subtypes characterized by MYC amplification (14%) or MYC overexpression (40%), both of which drive tumor proliferation, metabolic reprogramming, and cellular plasticity. MYC dysregulation is associated w...